Your browser doesn't support javascript.
At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy.
Novelli, Luca; Raimondi, Federico; Ghirardi, Arianna; Pellegrini, Dario; Capodanno, Davide; Sotgiu, Giovanni; Guagliumi, Giulio; Senni, Michele; Russo, Filippo M; Lorini, Ferdinando L; Rizzi, Marco; Barbui, Tiziano; Rambaldi, Alessandro; Cosentini, Roberto; Grazioli, Lorenzo S; Marchesi, Gianmariano; Sferrazza Papa, Giuseppe F; Cesa, Simonetta; Colledan, Michele; Civiletti, Roberta; Conti, Caterina; Casati, Monica; Ferri, Francesco; Camagni, Stefania; Sessa, Maria; Masciulli, Arianna; Gavazzi, Antonello; Falanga, Anna; DA Pozzo, Luigi F; Buoro, Sabrina; Remuzzi, Giuseppe; Ruggenenti, Piero; Callegaro, Annapaola; D'Antiga, Lorenzo; Pasulo, Luisa; Pezzoli, Fabio; Gianatti, Andrea; Parigi, Piercarlo; Farina, Claudio; Bellasi, Antonio; Solidoro, Paolo; Sironi, Sandro; DI Marco, Fabiano; Fagiuoli, Stefano.
  • Novelli L; Unit of Pulmonary Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Raimondi F; Unit of Pulmonary Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Ghirardi A; University of Milan, Milan, Italy.
  • Pellegrini D; FROM Research Foundation, Bergamo, Italy.
  • Capodanno D; Cardiovascular Department, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Sotgiu G; Unit of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy.
  • Guagliumi G; Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
  • Senni M; FROM Research Foundation, Bergamo, Italy.
  • Russo FM; FROM Research Foundation, Bergamo, Italy.
  • Lorini FL; University of Milan, Milan, Italy.
  • Rizzi M; Department of Emergency and Critical Care Area, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Barbui T; Department of Emergency and Critical Care Area, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Rambaldi A; Unit of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Cosentini R; University of Milan, Milan, Italy.
  • Grazioli LS; University of Milan, Milan, Italy.
  • Marchesi G; Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Sferrazza Papa GF; Emergency Department, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Cesa S; Department of Emergency and Critical Care Area, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Colledan M; Department of Emergency and Critical Care Area, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Civiletti R; University of Milan, Milan, Italy.
  • Conti C; Department of Neurorehabilitation Sciences, Casa di Cura del Policlinico, Milan, Italy.
  • Casati M; Department of Health and Social Care Professions, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Ferri F; Unit of General Surgery 3, Department of Organ Failure and Transplantation, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Camagni S; Unit of Pulmonary Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Sessa M; Federico II University, Naples, Italy.
  • Masciulli A; Unit of Pulmonary Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Gavazzi A; Department of Health and Social Care Professions, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Falanga A; Department of Emergency and Critical Care Area, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • DA Pozzo LF; Unit of General Surgery 3, Department of Organ Failure and Transplantation, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Buoro S; Unit of Neurology, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Remuzzi G; University of Milan, Milan, Italy.
  • Ruggenenti P; University of Milan, Milan, Italy.
  • Callegaro A; Unit of Immunohematology and Transfusion, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • D'Antiga L; University of Milano-Bicocca, Milan, Italy.
  • Pasulo L; University of Milano-Bicocca, Milan, Italy.
  • Pezzoli F; Unit of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Gianatti A; Unit of Quality Management, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Parigi P; Mario Negri Institute for Pharmacological Research IRCCS, Anna Maria Astori Centet, Kilometro Rosso Science and Technology Park, Bergamo, Italy.
  • Farina C; Unit of Nephrology and Dialysis, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Bellasi A; Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Solidoro P; Unit of Pediatric Hepatology Gastroenterology and Transplantation, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Sironi S; Unit of Gastroenterology 1, Hepatology and Transplantation, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • DI Marco F; Medical Direction, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Fagiuoli S; Unit of Pathology, Department of Laboratory Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.
Panminerva Med ; 63(1): 51-61, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1068211
ABSTRACT

BACKGROUND:

Findings from February 2020, indicate that the clinical spectrum of COVID-19 can be heterogeneous, probably due to the infectious dose and viral load of SARS-CoV-2 within the first weeks of the outbreak. The aim of this study was to investigate predictors of overall 28-day mortality at the peak of the Italian outbreak.

METHODS:

Retrospective observational study of all COVID-19 patients admitted to the main hospital of Bergamo, from February 23 to March 14, 2020.

RESULTS:

Five hundred and eight patients were hospitalized, predominantly male (72.4%), mean age of 66±15 years; 49.2% were older than 70 years. Most of patients presented with severe respiratory failure (median value [IQR] of PaO2/FiO2 233 [149-281]). Mortality rate at 28 days resulted of 33.7% (N.=171). Thirty-nine percent of patients were treated with continuous positive airway pressure (CPAP), 9.5% with noninvasive ventilation (NIV) and 13.6% with endotracheal intubation. 9.5% were admitted to Semi-Intensive Respiratory Care Unit, and 18.9% to Intensive Care Unit. Risk factors independently associated with 28-day mortality were advanced age (≥78 years odds ratio [OR], 95% confidence interval [CI] 38.91 [10.67-141.93], P<0.001; 70-77 years 17.30 [5.40-55.38], P<0.001; 60-69 years 3.20 [1.00-10.20], P=0.049), PaO2/FiO2<200 at presentation (3.50 [1.70-7.20], P=0.001), need for CPAP/NIV in the first 24 hours (8.38 [3.63-19.35], P<0.001), and blood urea value at admission (1.01 [1.00-1.02], P=0.015).

CONCLUSIONS:

At the peak of the outbreak, with a probable high infectious dose and viral load, older age, the severity of respiratory failure and renal impairment at presentation, but not comorbidities, are predictors of 28-day mortality in COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Age Factors / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Panminerva Med Year: 2021 Document Type: Article Affiliation country: S0031-0808.20.04063-X

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Age Factors / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Panminerva Med Year: 2021 Document Type: Article Affiliation country: S0031-0808.20.04063-X